What kind of fast should one be doing. >> If a patient is just simply looking to reduce his visceral fat, then I start with 1212, which means 12 hours you don't eat anything. You just drink liquids with no calories in it.And then 12 hours is your feeding period. We start with that and we do that for about 2 to 3 weeks. Then we quickly move to 186.186 means 6 hours you get to eat. 18 hours it's only water, black tea, black coffee, green tea, no calories. 186 186 and then that's one type of fasting.Now if a p ...

Core Insights - Veru Inc. is a late clinical stage biopharmaceutical company focused on developing innovative medicines for cardiometabolic and inflammatory diseases [3] - The company announced the presentation of two abstracts at ObesityWeek 2025, highlighting its drug enobosarm's potential in weight management [1][2] Company Overview - Veru Inc. is developing two late-stage novel small molecules: enobosarm and sabizabulin [3] - Enobosarm is a selective androgen receptor modulator (SARM) aimed at enhancing weight reduction by making fat loss more tissue-selective while preserving lean mass [3] - Sabizabulin is being developed for treating inflammation in atherosclerotic cardiovascular disease [3] Clinical Studies - The Phase 2b QUALITY clinical study demonstrated that enobosarm, when combined with semaglutide, led to greater fat loss while preserving lean mass in older patients [4] - The study involved 168 older patients (≥60 years) and showed that while weight loss was similar across treatment groups, the preservation of lean mass is expected to enhance energy expenditure [4] - A planned Phase 2b PLATEAU clinical study will evaluate enobosarm's effect on total body weight and physical function in approximately 200 patients initiating GLP-1 RA treatment [5][6] - The primary efficacy endpoint for the PLATEAU study is the percent change in total body weight at 72 weeks, with an interim analysis at 36 weeks [5][7]

[Music] isn't it lovely how beautiful how beauty is just a matter of nazaria or perspective and what better way to put that than our lyricists have speaking of nazaria did you know that Ganesha the Indian deity who is known as a vigna hara or the remover of obstacles today was once upon a time known as Vignna Karta the creator of obstacles. Confused. Let me explain.So in olden times whenever there was any flood or any famine people would attribute such natural catastrophes to an angry version of this dity w ...

Core Insights - WW International's share price increased by over 9% following the announcement of a collaboration with Amazon Pharmacy for distributing weight-management medications [1][2] - The partnership aims to simplify and expedite access to weight management medications for customers, as stated by the company's COO [3] - No specific estimates were provided regarding the financial impact of the Amazon deal, but it is expected to positively influence revenue and profitability [4] Company Developments - WW International signed a distribution agreement with Amazon Pharmacy to distribute its weight-management medications [2][6] - The company began offering compounded GLP-1 weight loss drugs under a subscription program in October 2024 [3] - The collaboration with Amazon is seen as a significant addition to the company's distribution channels for its products [4] Market Context - The stock performance of WW International outpaced the S&P 500, which saw a 1.1% increase on the same day [1] - Despite the positive stock movement, analysts from The Motley Fool Stock Advisor did not include WW International in their list of top investment recommendations [5][6]

Danish drugmaker Novo Nordisk was at the forefront of the weight-loss injection boom but struggled to keep up with runaway demand and misjudged the speed and scale of competition. Here’s what to know. https://t.co/JfbfVffwy4 ...

Morning, David. Well, Lily's GLP-1 pill or for Gipron besting Novo's GLP-1 pill in a phase three trial for type 2 diabetes. Now, this was the main goal was diabetes, but they also did look at weight loss.So, at the highest dose, Lily's pill over glyceron lowering blood sugar by 2.2% versus 1.4% for Novo's oral version of simaglutide. Lily's pill delivered weight loss of about 9% versus about 5% for Novos. But there is one really important caveat here and that's that Lily used about half the dose that Novo p ...

Lilly’s obesity pill prompted enough weight loss in a large clinical trial to be meaningful for patients and have far-reaching implications for the field, doctors said https://t.co/8uS45REPwH ...

Health Benefits of Fasting - Fasting is presented as a highly effective treatment for high blood pressure, a leading cause of death and disability [1] - Fasting can reduce insulin resistance and enhance cognitive capacities, potentially affecting depression and anxiety [1] - Fasting mobilizes visceral fat, which is linked to heart disease, cancer, and diabetes [2] - Chemical changes that happen with exercise also occur with fasting, such as increasing EDNF, a neurochemical protecting the brain from Alzheimer's disease [3][4] Societal and Lifestyle Context - The report highlights that 76% of people are overweight or obese, indicating a significant public health challenge [3] - The current environment is designed to promote unhealthy lifestyles, making people fat, sick, and miserable [3] Unique Selling Points of Fasting - Fasting is presented as a unique intervention with benefits beyond weight loss [5] - All human beings have the capacity to fast [4] - Water fasting has shown profound effects on conditions unresolved by medications, including polycystic ovarian syndrome [4]

and the obesity pill race. Mizuo healthcare strategist Jared Holtz joins us here on the set. You know, beyond just the patients being nauseous, investors are too today, down 42%.Is this it. I mean, are they done. Is Viking Therapeutics out of this race for the obesity pill.>> I don't think they're done. I mean, it's a it's a big setback for sure. It's going to come down to what the next trial looks like, what the dosing is, but this sort of discontinuation rate when you have monster companies that are ahead ...

Clinical Trial Results - Eli Lilly's experimental pill Orphon showed an 11% weight loss in patients [1] - Novo Nordisk's weight loss shot Wegovy led to a 15% body weight reduction in trials [2] - Eli Lilly's shot Zepbound demonstrated even better weight loss results than Wegovy [2] Market Expectations and Reactions - Wall Street anticipated Orphon to perform better, aligning with injectable drugs [1] - Investors showed a negative reaction to Orphon's results, indicated by a share price decrease [1] - Pills are considered crucial for expanding market reach, in a market projected to reach $95 billion by 2030 [3] Development and Approval - Eli Lilly plans to submit Orphon's findings for approval by the end of the year [4] - The daily weight loss pill could potentially be available in pharmacies as early as 2026, pending approval [4] - Pharmaceutical companies like Pfizer and AstraZeneca have previously encountered setbacks in developing weight loss pills [3]